Covid-19 New

More Info

Open access Aims and Scope Instructions Editorial Guidelines Licensing Copyright

Author's satisfaction with

  • Friendly and hassle-free publication process
  • Less production time of articles
  • Constructive peer-review
  • Enhancing journal reputation
  • Regular feedback system
  • Quick response to authors' queries

Read More

Recently Viewed

Metabolic syndrome: A case report The Ramifications of Loneliness: A Commentary Antimicrobial, Antioxidant Activity of Ethyl Acetate Extract Jaw Subluxation as a Complication of Tardive Dyskinesia Symmetry of Shank Muscle Strength, Passive Stiffness and Pla

Read More

Most Viewed

Evaluation of Biostimulants Based on Recovered Protein Hydro Feasibility study of magnetic sensing for detecting single-n Sinonasal Myxoma Extending into the Orbit in a 4-Year Old: A Pediatric Dysgerminoma: Unveiling a Rare Ovarian Tumor Physical activity can change the physiological and psycholog

Read More

Open Journals

Clinical Images

For Authors Guide For Authors Benefits For Authors Article Processing Charge How To Write a Scientific Paper How To Write a Review Article Short Communication
For Reviewers Benefits For Reviewers How To Review Thanks To Reviewers
For Editors Benefits For Editors Thanks To Editors

Abstract

Review Article

Imaging modalities delivery of RNAi therapeutics in cancer therapy and clinical applications

Loutfy H Madkour*

Published: 04 March, 2021 | Volume 5 - Issue 1 | Pages: 005-034

The RNA interference (RNAi) technique is a new modality for cancer therapy, and several candidates are being tested clinically. Nanotheranostics is a rapidly growing field combining disease diagnosis and therapy, which ultimately may add in the development of ‘personalized medicine’.

Technologies on theranostic nanomedicines has been discussed. We designed and developed bioresponsive and fluorescent hyaluronic acid-iodixanol nanogels (HAI-NGs) for targeted X-ray computed tomography (CT) imaging and chemotherapy of MCF-7 human breast tumors. HAI-NGs were obtained with a small size of ca. 90 nm, bright green fluorescence and high serum stability from hyaluronic acid-cystamine-tetrazole and reductively degradable polyiodixanol-methacrylate via nanoprecipitation and a photo-click crosslinking reaction. This chapter presents an over view of the current status of translating the RNAi cancer therapeutics in the clinic, a brief description of the biological barriers in drug delivery, and the roles of imaging in aspects of administration route, systemic circulation, and cellular barriers for the clinical translation of RNAi cancer therapeutics, and with partial content for discussing the safety concerns. Finally, we focus on imaging-guided delivery of RNAi therapeutics in preclinical development, including the basic principles of different imaging modalities, and their advantages and limitations for biological imaging. With growing number of RNAi therapeutics entering the clinic, various imaging methods will play an important role in facilitating the translation of RNAi cancer therapeutics from bench to bedside.

Read Full Article HTML DOI: 10.29328/journal.jro.1001035 Cite this Article Read Full Article PDF

Keywords:

Molecular imaging; Cancer; Nanocarrier; siRNA; RNA interference; Gene delivery; Theranostics; X-ray computed tomography

References

  1. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, et al, Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998; 391: 806–811. PubMed: https://pubmed.ncbi.nlm.nih.gov/9486653/
  2. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells, Nature. 2001; 411: 494–498. PubMed: https://pubmed.ncbi.nlm.nih.gov/11373684/
  3. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012—an update. J Gene Med. 2013; 15: 65–77. PubMed: https://pubmed.ncbi.nlm.nih.gov/23355455/
  4. Thi EP, Mire CE, Ursic-Bedoya R, Geisbert JB, Lee ACH, et al. Marburg virus infection in nonhuman primates: therapeutic treatment by lipid-encapsulated siRNA. Sci Transl Med. 2014; 6: 250ra116. PubMed: https://pubmed.ncbi.nlm.nih.gov/25143366/
  5. Kaiser PK, Symons RC, Shah SM, Quinlan EJ, Tabandeh H, et al. RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Am J Ophthalmol. 2010; 150: 33–39. PubMed: https://pubmed.ncbi.nlm.nih.gov/20609706/
  6. O'Connell RM, Rao DS, Chaudhuri AA, Baltimore D. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol. 2010; 10: 111–122. PubMed: https://pubmed.ncbi.nlm.nih.gov/20098459/
  7. van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov. 2012; 11: 860–872. PubMed: https://pubmed.ncbi.nlm.nih.gov/23080337/
  8. Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013; 369: 819–829. PubMed: https://pubmed.ncbi.nlm.nih.gov/23984729/
  9. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010; 464: 1067–1070. PubMed: https://pubmed.ncbi.nlm.nih.gov/20305636/
  10. Shen H, Sun T, Ferrari M. Nanovector delivery of siRNA for cancer therapy. Cancer Gene Ther. 2012; 19: 367–373. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842228/
  11. Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013; 3: 406–417. PubMed: https://pubmed.ncbi.nlm.nih.gov/23358650/
  12. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008; 5: 505–515. PubMed: https://pubmed.ncbi.nlm.nih.gov/18672949/
  13. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2010; 8: 129–138. PubMed: https://pubmed.ncbi.nlm.nih.gov/19180106/
  14. Li W, Szoka FC, Jr. Lipid-based nanoparticles for nucleic acid delivery. Pharm Res. 2007; 24: 438–449. PubMed: https://pubmed.ncbi.nlm.nih.gov/17252188/
  15. Mintzer MA, Simanek EE. Nonviral vectors for gene delivery. Chem Rev. 2009; 109: 259–302. PubMed: https://pubmed.ncbi.nlm.nih.gov/19053809/
  16. Zumbuehl AA, Goldberg M, Leshchiner ES, Busini V, Hossain N, et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol. 2008; 26: 561–569. PubMed: https://pubmed.ncbi.nlm.nih.gov/18438401/
  17. Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010; 28: 172–176. PubMed: https://pubmed.ncbi.nlm.nih.gov/20081866/
  18. Lee CC, MacKay JA, Frechet JM, Szoka FC. Designing dendrimers for biological applications. Nat Biotechnol. 2005; 23: 1517–1526. PubMed: https://pubmed.ncbi.nlm.nih.gov/16333296/
  19. Pack DW, Hoffman AS, Pun S, Stayton PS. Design and development of polymers for gene delivery. Nat Rev Drug Discov. 2005; 4: 581–593. PubMed: https://pubmed.ncbi.nlm.nih.gov/16052241/
  20. Thomas M, Klibanov AM. Non-viral gene therapy: polycation-mediated DNA delivery. Appl Microbiol Biotechnol. 2003; 62: 27–34. PubMed: https://pubmed.ncbi.nlm.nih.gov/12719940/
  21. Mo RH, Zaro JL, Shen WC. Comparison of cationic and amphipathic cell penetrating peptides for siRNA delivery and efficacy. Mol Pharm. 2012; 9: 299–309. PubMed: https://pubmed.ncbi.nlm.nih.gov/22171592/
  22. Martin ME, Rice KG. Peptide-guided gene delivery. AAPS J. 2007; 9: E18–E29. PubMed: https://pubmed.ncbi.nlm.nih.gov/17408236/
  23. Dassie JP, Liu XY, Thomas GS, Whitaker RM, Thiel KW, et al, Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMAexpressing tumors. Nat Biotechnol. 2009; 27: 839–849. PubMed: https://pubmed.ncbi.nlm.nih.gov/19701187/
  24. Yao YD, Sun TM, Huang SY, Dou S, Lin L, et al. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis. Sci Transl Med. 2012; 4: 130ra148. PubMed: https://pubmed.ncbi.nlm.nih.gov/22517885/
  25. Choi KY, Silvestre OF, Huang X, Hida N, Liu G, et al. A nanoparticle formula for delivering siRNA or miRNAs to tumor cells in cell culture and in vivo. Nat Protoc. 2014; 9: 1900–1915. PubMed: https://pubmed.ncbi.nlm.nih.gov/25033207/
  26. Choi KY, Silvestre OF, Huang X, Min KH, Howard GP, et al. Versatile RNA interference nanoplatform for systemic delivery of RNAs. ACS Nano. 2014; 8: 4559–4570. PubMed: https://pubmed.ncbi.nlm.nih.gov/24779637/
  27. Liu G, Choi KY, Bhirde A, Swierczewska M, Yin J, et al. Sticky nanoparticles: a platform for siRNA delivery by a bis(zinc(II) dipicolylamine)-functionalized, self-assembled nanoconjugate. Angew Chem Int. 2012; 51: 445–449. PubMed: https://pubmed.ncbi.nlm.nih.gov/22110006/
  28. Sokolova V, Epple M. Inorganic nanoparticles as carriers of nucleic acids into cells. Angew Chem Int. Ed Engl. 2008; 47: 1382–1395. PubMed: https://pubmed.ncbi.nlm.nih.gov/18098258/
  29. Afonin KA, Viard M, Koyfman AY, Martins AN, Kasprzak WK, et al. Multifunctional RNA nanoparticles. Nano Lett. 2014; 14: 5662–5671. PubMed: https://pubmed.ncbi.nlm.nih.gov/25267559/
  30. Cui DX, Zhang CL, Liu B, Shu Y, Du T, et al. Regression of gastric cancer by systemic injection of RNA nanoparticles carrying both ligand and siRNA. Sci Rep. 2015; 5: e10726. PubMed: https://pubmed.ncbi.nlm.nih.gov/26137913/
  31. Lee H, Lytton-Jean AKR, Chen Y, Love KT, Park AI, et al. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat Nanotechnol. 2012; 7: 389–393. PubMed: https://pubmed.ncbi.nlm.nih.gov/22659608/
  32. Rychahou P, Haque F, Shu Y, Zaytseva Y, Weiss HL, et al. Delivery of RNA nanoparticles into colorectal cancer metastases following systemic administration. ACS Nano. 2015; 9: 1108–1116. PubMed: https://pubmed.ncbi.nlm.nih.gov/25652125/
  33. Shu D, Li H, Shu Y, \Xiong G, Carson WE, 3rd, et al. Systemic delivery of anti-miRNA for suppression of triple negative breast cancer utilizing RNA nanotechnology. ACS Nano. 2015; 9: 9731–9740. PubMed: https://pubmed.ncbi.nlm.nih.gov/26387848/
  34. Haussecker D. Current issues of RNAi therapeutics delivery and development. J Control Release. 2014; 195: 49–54. PubMed: https://pubmed.ncbi.nlm.nih.gov/25111131/
  35. Wang J, Lu Z, Wientjes MG, Au JLS. Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 2010; 12: 492–503. PubMed: https://pubmed.ncbi.nlm.nih.gov/20544328/
  36. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, et al.Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med. 2005; 11: 263–270. PubMed: https://pubmed.ncbi.nlm.nih.gov/15723075/
  37. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, et al. Sequencedependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol. 2005; 23: 457–462. PubMed: https://pubmed.ncbi.nlm.nih.gov/15778705/
  38. Jackson AL, Burchard J, Schelter J, Chau BN, Cleary M, et al. Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity. RNA. 2006; 12: 1179–1187. PubMed: https://pubmed.ncbi.nlm.nih.gov/16682560/
  39. Hong H, Zhang Y, Cai WB. in vivo imaging of RNA Interference. J Nucl Med. 2010; 51: 169–172. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2832477/
  40. Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat Rev Drug Discov. 2008; 7: 591–607. PubMed: https://pubmed.ncbi.nlm.nih.gov/18591980/
  41. Wu SY, Lopez-Berestein G, Calin GA, Sood AK. RNAi therapies: drugging the undruggable. Sci Transl Med. 2014; 6: 240–247. PubMed: https://pubmed.ncbi.nlm.nih.gov/24920658/
  42. Contag CH, Bachmann MH. Advances in in vivo bioluminescence imaging of gene expression. Annu Rev Biomed Eng. 2002; 4: 235–260. PubMed: https://pubmed.ncbi.nlm.nih.gov/12117758/
  43. Wang F, Song X, Li X, Xin J, Wang S, et al. Noninvasive visualization of microRNA-16 in the chemoresistance of gastric cancer using a dual reporter gene imaging system. PLoS ONE. 2013; 8: e61792. PubMed: https://pubmed.ncbi.nlm.nih.gov/23613938/
  44. Huang X, Lee S, Chen X. Design of “smart” probes for optical imaging of apoptosis. Am J Nucl Med Mol Imaging. 2011; 1: 3–17. PubMed: https://pubmed.ncbi.nlm.nih.gov/22514789/
  45. Sosnovik DE, Weissleder R. Emerging concepts in molecular MRI. Curr Opin Biotechnol. 2007; 18: 4–10. PubMed: https://pubmed.ncbi.nlm.nih.gov/17126545/
  46. Alauddin MM. Positron emission tomography (PET) imagingwith (18)F-based radiotracers. Am J Nucl Med Mol Imaging. 2012; 2: 55–76. PubMed: https://pubmed.ncbi.nlm.nih.gov/23133802/
  47. Bhargava P, He G, Samarghandi A, Delpassand ES. Pictorial review of SPECT/CT imaging applications in clinical nuclear medicine. Am J Nucl Med Mol Imaging. 2012; 2: 221–231. PubMed: https://pubmed.ncbi.nlm.nih.gov/23133813/
  48. Dayton PA, Rychak JJ. Molecular ultrasound imaging using microbubble contrast agents. Front Biosci. 2007; 12: 5124–5142. PubMed: https://pubmed.ncbi.nlm.nih.gov/17569635/
  49. Pai SI, Lin YY, Macaes B, Meneshian A, Hung CF, et al. Prospects of RNA interference therapy for cancer. Gene Ther. 2006; 13: 464–477. PubMed: https://pubmed.ncbi.nlm.nih.gov/16341059/  
  50. Rao DD, Wang ZH, Senzer N, Nemunaitis J. RNA Interference and personalized cancer therapy. Discov Med. 2013; 81: 101–110. PubMed: https://pubmed.ncbi.nlm.nih.gov/23449112/
  51. D.A.C. Center. EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery (IND# 72924): A Phase I Clinical Trial. https://clinicaltrials.gov/cT2/ show/NCT01591356/term=NCT015913562012   
  52. C.C.o.W.F. University, A Phase 1, Open-Label, Dose-Ranging Study to Assess the Safety and Immunologic Activity of APN401. https://clinicaltrials.gov/cT2/show/NCT021662552014
  53. Pruitt S. Phase I Study of Active Immunotherapy ofMetastaticMelanomawithMature Autologous Dendritic Cells Transfectedwith Tumor Antigen RNA and Small Inhibitory RNAs to Alter Proteasomal Antigen Processing. https://clinicaltrials.gov/cT2/show/NCT006725422008
  54. T. GmbH, A Prospective, Open-label, Single Center, Dose Finding Phase I-Study with Atu027 (an siRNA Formulation) in Subjects with Advanced Solid Cancer. https://clinicaltrials.gov/cT2/show/NCT009385742009
  55. Ltd, Phase I—Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in PatientsWith Non-operable Adenocarcinoma of the Pancreas. https://clinicaltrials.gov/cT2/show/NCT011887852010
  56. C.I. (NCI), A Phase 1 Dose Escalation Study of Hepatic Intra-Arterial Administration of TKM 080301 (Lipid Nanoparticles Containing siRNA Against the PLK1 Gene Product) in Patients with Colorectal, Pancreas, Gastric, Breast, Ovarian and Esophageal Cancers with Hepatic. https://clinicaltrials.gov/cT2/show/NCT014370072011
  57. D. Corporation, A Phase 1b/2, Open Label, Randomized, Repeat Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Biological Activity, and Pharmacokinetics of ND-L02-s0201 Injection, a Vitamin A-coupled Lipid Nanoparticle Containing siRNA Against HSP47, in Subjects with Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4). https://clinicaltrials.gov/cT2/show/NCT022274592014
  58. Dicerna Pharmaceuticals, Phase I,Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma. https://clinicaltrials.gov/cT2/show/NCT021105632014
  59. Pharmaceuticals, A Phase I, Dose-Escalating Study of the Safety of Intravenous CALAA-01 in Adults with Solid Tumors Refractory to Standard-of-Care Therapies. https://clinicaltrials.gov/cT2/show/NCT006890652008
  60. P. Corporation, A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients with Advanced Solid Tumors. https://clinicaltrials.gov/cT2/show/NCT012622352010
  61. Pharmaceuticals, A Multi-Center, Open Label, Phase 1 Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 in Patients with Advanced Solid Tumors with Liver Involvement. https://clinicaltrials.gov/cT2/show/NCT008821802009
  62. Pharmaceuticals, A Multi-center, Open-Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment. https://clinicaltrials.gov/cT2/show/NCT011580792009
  63. Aleku SM, Schulz P, Keil O, Santel A, Schaeper U, et al. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res. 2008; 68: 9788–9798. PubMed: https://pubmed.ncbi.nlm.nih.gov/19047158/
  64. Aleku SM, Roder N, Mopert K, Durieux B, Janke O, et al. Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models. Clin Cancer Res. 2010; 16: 5469–5480. PubMed: https://pubmed.ncbi.nlm.nih.gov/21062934/
  65. Leenders F, Mopert K, Schmiedeknecht A, Santel A, Czauderna F, et al. PKN3 is required formalignant prostate cell growth downstream of activated PI 3-kinase. EMBO J. 2004; 23: 3303–3313. PubMed: https://pubmed.ncbi.nlm.nih.gov/15282551/
  66. Strumberg D, Schultheis B, Traugott U, Vank C, Santel A, et al. Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. Int J Clin Pharmacol Ther. 2012; 50: 76–78. PubMed: https://pubmed.ncbi.nlm.nih.gov/22192654/
  67. Schultheis B, Strumberg D, Santel A, Vank C, Gebhardt F, et al. First-in-human phase I study of the liposomal RNA Interference therapeutic Atu027 in patients with advanced solid tumors. J Clin Oncol. 2014; 32: 4141–4148. PubMed: https://pubmed.ncbi.nlm.nih.gov/25403217/
  68. Blangy A, Lane HA, d'Herin P, Harper M, Kress M, et al. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell. 1995; 83: 1159–1169. PubMed: https://pubmed.ncbi.nlm.nih.gov/8548803/
  69. Itakura J, Ishiwata T, Shen B, Kornmann M, Korc M. Concomitant overexpression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer. 2000; 85: 27–34. PubMed: https://pubmed.ncbi.nlm.nih.gov/10585578/
  70. Boocock CA, Charnockjones DS, Sharkey AM, Mclaren J, Barker PJ, et al. Expression of vascular endothelial growth-factor and its receptors Flt and Kdr in ovarian-carcinoma. J Natl Cancer Inst. 1995; 87: 506–516. PubMed: https://pubmed.ncbi.nlm.nih.gov/7707437/
  71. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003; 9: 669–676. PubMed: https://pubmed.ncbi.nlm.nih.gov/12778165/
  72. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine, Oncogene. 2004; 23: 1539–1548. PubMed: https://pubmed.ncbi.nlm.nih.gov/14661056/
  73. Wang YX, Ng CK. The impact of quantitative imaging in medicine and surgery: charting our course for the future. Quant Imaging Med Surg. 2011; 1: 1–3. PubMed: https://pubmed.ncbi.nlm.nih.gov/23256048/
  74. Tracy Zimmermann VK, Harrop J, Chan A, Chiesa J, Peters G, et al. Phase I First-in-Human Trial of ALN-TTRsc, a Novel RNA Interference Therapeutic for the Treatment of Familial Amyloidotic Cardiomyopathy (FAC). http://www.alnylam.com/web/wp-content/uploads/2013/09/ALN-TTRsc-PhI-HFSA-Poster-Sep2013.pdf2013
  75. Buyens K, De Smedt SC, Braeckmans K, Demeester J, Peeters L, et al. Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design. J Control Release. 2012; 158: 362–370. PubMed: https://pubmed.ncbi.nlm.nih.gov/22023849/
  76. Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat Mater. 2013; 12: 967–977.
  77. Oh YK, Park TG. siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev. 2009; 61: 850–862. PubMed: https://pubmed.ncbi.nlm.nih.gov/19422869/
  78. Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, et al. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014; 15: 541–555. PubMed: https://pubmed.ncbi.nlm.nih.gov/25022906/
  79. Zhang P, Chen Y, Zeng Y, Shen C, Li R, et al. Virus-mimetic nanovesicles as a versatile antigen-delivery system. Proc Natl Acad Sci. U S A. 2015; 112: E6129–E6138. PubMed: https://pubmed.ncbi.nlm.nih.gov/26504197/
  80. Kobayashi H, Watanabe R, Choyke PL. Improving conventional enhanced permeability and retention (EPR) effects; what Is the appropriate Target? Theranostics. 2014; 4: 81–89. PubMed: https://pubmed.ncbi.nlm.nih.gov/24396516/
  81. Matsumura Y, Maeda H, A new concept for macromolecular therapeutics in cancer- chemotherapy—mechanism of tumoritropic accumulation of proteins and the antitumor agent Smancs. Cancer Res. 1996; 46: 6387–6392. PubMed: https://pubmed.ncbi.nlm.nih.gov/2946403/
  82. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001; 53: 283–318. PubMed: https://pubmed.ncbi.nlm.nih.gov/11356986/
  83. Cho KJ, Wang X, Nie SM, Chen Z, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008; 14: 1310–1316. PubMed: https://pubmed.ncbi.nlm.nih.gov/18316549/
  84. van Vlerken LE, Vyas TK, Amiji MM. Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm Res. 2007; 24: 1405–1414. PubMed: https://pubmed.ncbi.nlm.nih.gov/17393074/
  85. Maclachlan I, Cullis P. Diffusible-PEG-lipid stabilized plasmid lipid particles. Adv Genet. 2005; 157: 188 53pa. PubMed: https://pubmed.ncbi.nlm.nih.gov/16243063/
  86. Vaupel P, Kallinowski F, Okunieff P. Blood-flow, oxygen and nutrient supply, and metabolic microenvironment of human-tumors—a review. Cancer Res. 1989; 49: 6449–6465. PubMed: https://pubmed.ncbi.nlm.nih.gov/2684393/
  87. Li L, Wang R, Wilcox D, Zhao X, Song J, et al. Tumor vasculature is a key determinant for the efficiency of nanoparticlemediated siRNA delivery. Gene Ther. 2012; 19: 775–780. PubMed: https://pubmed.ncbi.nlm.nih.gov/21956688/
  88. Huang K, Ma H, Liu J, Huo S, Kumar A, et al. Size-dependent localization and penetration of ultrasmall gold nanoparticles in cancer cells, multicellular spheroids, and tumors in vivo. ACS Nano. 2012; 6: 4483–4493. PubMed: https://pubmed.ncbi.nlm.nih.gov/22540892/
  89. Cunha L, Szigeti K, Mathe D, Metello LF. The role ofmolecular imaging inmodern drug development. Drug Discov Today. 2014; 19: 936–948. PubMed: https://pubmed.ncbi.nlm.nih.gov/24434047/
  90. Meade BR, Dowdy SF. Exogenous siRNA delivery using peptide transduction domains/ cell penetrating peptides. Adv Drug Deliv Rev. 2007; 59: 134–140. PubMed: https://pubmed.ncbi.nlm.nih.gov/17451840/
  91. Rozema DB, Lewis DL, Wakefield DH, Wong SC, Klein JJ, et al. Dynamic polyconjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci. U S A. 2007; 104: 12982–12987. PubMed: https://pubmed.ncbi.nlm.nih.gov/17652171/
  92. Cardoso AL, Simoes S, de Almeida LP, Pelisek J, Culmsee C, et al. siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing. J Gene Med. 2007; 9: 170–183. PubMed: https://pubmed.ncbi.nlm.nih.gov/17351968/
  93. Chu TC, Twu KY, Ellington AD, Levy M. Aptamer mediated siRNA delivery. Nucleic Acids Res. 2006; 34: e73. PubMed: https://pubmed.ncbi.nlm.nih.gov/16740739/
  94. Lorenzer C, Dirin M, Winkler AM, Baumann V, Winkler J. Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics. J Control Release. 2015; 203: 1–15. PubMed: https://pubmed.ncbi.nlm.nih.gov/25660205/
  95. Gruenberg J, van der Goot FG. Mechanisms of pathogen entry through the endosomal compartments. Nat Rev Mol Cell Biol. 2006; 7: 495–504. PubMed: https://pubmed.ncbi.nlm.nih.gov/16773132/
  96. Sonawane ND, Szoka FC, Jr., Verkman AS. Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. J Biol Chem. 2003; 278: 44826–44831. PubMed: https://pubmed.ncbi.nlm.nih.gov/12944394/
  97. Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci. U S A. 1995; 92: 7297–7301. PubMed: https://pubmed.ncbi.nlm.nih.gov/7638184/
  98. Qiu S, Adema CM, Lane T. A computational study of off-target effects of RNA interference. Nucleic Acids Res. 2005; 33: 1834–1847. PubMed: https://pubmed.ncbi.nlm.nih.gov/15800213/
  99. Goodchild A, Nopper N, King A, Doan T, Tanudji M, et al. Sequence determinants of innate immune activation by short interfering RNAs. BMC Immunol. 2009; 10: 40. PubMed: https://pubmed.ncbi.nlm.nih.gov/19630977/
  100. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, et al. Sequence dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol. 2005; 23: 457–462. PubMed: https://pubmed.ncbi.nlm.nih.gov/15778705/
  101. Sioud M. Does the understanding of immune activation by RNA predict the design of safe siRNAs? Front Biosci. 2008; 13: 4379–4392. PubMed: https://pubmed.ncbi.nlm.nih.gov/18508517/
  102. Sevick-Muraca EM, Houston JP, Gurfinkel M. Fluorescence-enhanced, near infrared diagnostic imaging with contrast agents. Curr Opin Chem Biol. 2002; 6: 642–650. PubMed: https://pubmed.ncbi.nlm.nih.gov/12413549/
  103. Frangioni JV. in vivo near-infrared fluorescence imaging. Curr Opin Chem Biol. 2003; 7: 626–634. PubMed: https://pubmed.ncbi.nlm.nih.gov/14580568/
  104. Zanzonico P. Noninvasive imaging for supporting basic research, Small Animal Imaging: Basics and Practical Guide. 2011; 3–16.
  105. Leblond F, Davis SC, Valdés PA, Pogue BW. Pre-clinical whole-body fluorescence imaging: review of instruments, methods and applications. J Photochem Photobiol. 2010; 98: 77–94. PubMed: https://pubmed.ncbi.nlm.nih.gov/20031443/
  106. Guo Z, Park S, Yoon J, Shin I. Recent progress in the development of near-infrared fluorescent probes for bioimaging applications. Chem Soc Rev. 2014; 43: 16–29.
  107. Kim SH, Jeong JH, Lee SH, Kim SW, Park TG. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J Control Release. 2008; 129: 107–116. PubMed: https://pubmed.ncbi.nlm.nih.gov/18486981/
  108. Gilleron J, Querbes W, Zeigerer A, Borodovsky A, Marsico G, et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol. 2013; 31: 638–646. PubMed: https://pubmed.ncbi.nlm.nih.gov/23792630/
  109. Chang E, Zhu MQ, Drezek R. Novel siRNA-based molecular beacons for dual imaging and therapy. Biotechnol J. 2007; 2: 422–425. PubMed: https://pubmed.ncbi.nlm.nih.gov/17330221/
  110. Christie RJ, Matsumoto Y, Miyata K, Nomoto T, Fukushima S, et al. Targeted polymeric micelles for siRNA treatment of experimental cancer by intravenous injection. ACS Nano. 2012; 6: 5174–5189. PubMed: https://pubmed.ncbi.nlm.nih.gov/22575090/
  111. Christie RJ, Miyata K, Matsumoto Y, Nomoto T, Menasco D, et al. Effect of polymer structure on micelles formed between siRNA and cationic block copolymer comprising thiols and amidines. Biomacromolecules. 2011; 12: 3174–3185. PubMed: https://pubmed.ncbi.nlm.nih.gov/21863796/
  112. Oe Y, Christie RJ, Naito M, Low SA, Fukushima S, et al. Actively-targeted polyion complex micelles stabilized by cholesterol and disulfide cross-linking for systemic delivery of siRNA to solid tumors. Biomaterials. 2014; 35: 7887–7895. PubMed: https://pubmed.ncbi.nlm.nih.gov/24930854/
  113. Chen AA, Derfus AM, Khetani SR, Bhatia SN. Quantum dots tomonitor RNAi delivery and improve gene silencing. Nucleic Acids Res. 2005; 33: e190. PubMed: https://pubmed.ncbi.nlm.nih.gov/16352864/
  114. Wang J, Zhang P, Huang C, Liu G, Leung KC, et al. High performance photoluminescent carbon dots for in vitro and in vivo bioimaging: effect of nitrogen doping ratios. Langmuir. 2015; 31: 8063–8073. PubMed: https://pubmed.ncbi.nlm.nih.gov/26135003/
  115. Jiang S, Zhang Y, Lim KM, Sim EKW, Ye L. NIR-to-visible upconversion nanoparticles for fluorescent labeling and targeted delivery of siRNA. Nanotechnology. 2009; 20: e155101. PubMed: https://pubmed.ncbi.nlm.nih.gov/19420539/
  116. Jung J, Solanki A, Memoli KA, Kamei K, Kim H, et al. Selective inhibition of human brain tumor cells through multifunctional quantum-dot-based siRNA delivery. Angew Chem Int Ed. 2010; 49: 103–107. PubMed: https://pubmed.ncbi.nlm.nih.gov/19950159/
  117. Wang J, Liu G, Leung KC, Loffroy R, Lu PX, et al. Opportunities and challenges of fluorescent carbon dots in translational optical imaging. Curr Pharm Des. 2015; 21: 5401–5416. PubMed: https://pubmed.ncbi.nlm.nih.gov/26377656/
  118. Wang L, Wang X, Bhirde A, Cao J, Zeng Y, et al. Carbon- dot-based two-photon visible nanocarriers for safe and highly efficient delivery of siRNA and DNA. Adv Health Mater. 2014; 3: 1203–1209. PubMed: https://pubmed.ncbi.nlm.nih.gov/24692418/
  119. Chatterjee DK, Gnanasammandhan Y, Fau-Zhang MK, Zhang Y. Small upconverting fluorescent nanoparticles for biomedical applications. Small. 2010; 6: 2781–2795. PubMed: https://pubmed.ncbi.nlm.nih.gov/21064086/
  120. Wang L, Liu J, Dai Y, Yang Q, Zhang Y, et al. Efficient gene delivery and multimodal imaging by lanthanide-based upconversion nanoparticles. Langmuir. 2014; 30: 13042–13051. PubMed: https://pubmed.ncbi.nlm.nih.gov/25291048/
  121. Nayak TR, Krasteva LK, Cai W. Multimodality imaging of RNA Interference. Curr Med Chem. 2013; 20: 3664–3675. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749287/
  122. McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ, et al. RNA interference in adult mice. Nature. 2002; 418: 38–39. PubMed: https://pubmed.ncbi.nlm.nih.gov/12097900/
  123. Lewis DL, Hagstrom JE, Loomis AG, Wolff JA, Herweijer H. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat Genet. 2002; 32: 107–108. PubMed: https://pubmed.ncbi.nlm.nih.gov/12145662/
  124. Pichler A, Zelcer N, Prior JL, Kuil AJ, Piwnica-Worms D. In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. Clin Cancer Res. 2005; 11: 4487–4494. PubMed: https://pubmed.ncbi.nlm.nih.gov/15958634/
  125. Pittella F, Cabral H, Maeda Y, Mi P, Watanabe S, et al. Systemic siRNA delivery to a spontaneous pancreatic tumor model in transgenic mice by PEGylated calcium phosphate hybrid micelles. J Control Release. 2014; 178: 18–24. PubMed: https://pubmed.ncbi.nlm.nih.gov/24440662/
  126. Bartlett DW, Davis ME. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res. 2006; 34: 322–333. PubMed: https://pubmed.ncbi.nlm.nih.gov/16410612/
  127. Kim SH, Mok H, Jeong JH, Kim SW, Park TG. Comparative evaluation of targetspecific GFP gene silencing efficiencies for antisense ODN, synthetic siRNA, and siRNA plasmid complexed with PEI-PEG-FOL conjugate. Bioconjug Chem. 2006; 17: 241–244. PubMed: https://pubmed.ncbi.nlm.nih.gov/16417275/
  128. Huschka R, Barhoumi A, Liu Q, Roth JA, Ji L, et al. Gene silencing by gold nanoshell-mediated delivery and laser-triggered release of antisense oligonucleotide and siRNA. ACS Nano. 2012; 6: 7681–7691. PubMed: https://pubmed.ncbi.nlm.nih.gov/22862291/
  129. James ML, Gambhir SS. A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev. 2012; 92: 897–965. PubMed: https://pubmed.ncbi.nlm.nih.gov/22535898/
  130. Phelps ME. Positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci U S A. 2000; 97: 9226–9233. PubMed: https://pubmed.ncbi.nlm.nih.gov/10922074/
  131. Ziegler SI. Positron emission tomography: principles, technology, and recent developments. Nucl Phys A. 2005; 752: 679c–687c.
  132. Lammers T, Aime S, Hennink WE, Storm G, Kiessling F. Theranostic nanomedicine. Acc Chem Res. 2011; 44: 1029–1038. PubMed: https://pubmed.ncbi.nlm.nih.gov/21545096/
  133. Lu W, Zhang G, Zhang R, Flores LG,2nd, Huang Q, et al. Tumor sitespecific silencing of NF-kappaB p65 by targeted hollow gold nanosphere-mediated photothermal transfection. Cancer Res. 2010; 70: 3177–3188. PubMed: https://pubmed.ncbi.nlm.nih.gov/20388791/
  134. Nayak TR, Krasteva LK, Cai W. Multimodality imaging of RNA interference. Curr Med Chem. 2013; 20: 3664–3675. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749287/
  135. Hatanaka K, Asai T, Koide H, Kenjo E, Tsuzuku T, et al. Development of double-stranded siRNA labeling method using positron emitter and its in vivo trafficking analyzed by positron emission tomography. Bioconjug Chem. 2010; 21: 756–763.
  136. Lu FM, Yuan Z. PET/SPECT molecular imaging in clinical neuroscience: recent advances in the investigation of CNS diseases. Quant Imaging Med Surg. 2015; 5: 433–447. PubMed: https://pubmed.ncbi.nlm.nih.gov/26029646/
  137. Liu N, Ding H, Vanderheyden JL, Zhu Z, Zhang Y. Radiolabeling small RNA with technetium-99 m for visualizing cellular delivery and mouse biodistribution. Nucl Med Biol. 2007; 34: 399–404. PubMed: https://pubmed.ncbi.nlm.nih.gov/17499729/
  138. Merkel OM, Librizzi D, Pfestroff A, Schurrat T, Behe M, et al. In vivo SPECT and real-time gamma camera imaging of biodistribution and pharmacokinetics of siRNA delivery using an optimized radiolabeling and purification procedure. Bioconjug Chem. 2009; 20: 174–182. PubMed: https://pubmed.ncbi.nlm.nih.gov/19093855/
  139. Faulkner W. Basic Principles of MRIOutSource 1996.
  140. Wang YX. Super paramagnetic iron oxide based MRI contrast agents: current status of clinical application. Quant Imaging Med Surg. 2011; 1: 35–40. PubMed: https://pubmed.ncbi.nlm.nih.gov/23256052/
  141. Mok H, Veiseh O, Fang C, Kievit FM, Wang FY, et al. pH-sensitive siRNA nanovector for targeted gene silencing and cytotoxic effect in cancer cells. Mol Pharm. 2010; 7: 1930–1939. PubMed: https://pubmed.ncbi.nlm.nih.gov/20722417/
  142. Shen M, Gong F, Pang P, Zhu K, Meng X, et al. An MRI-visible non-viral vector for targeted Bcl-2 siRNA delivery to neuroblastoma. Int J Nanomed. 2012; 7: 3319–3332. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396391/
  143. Li C, Penet MF, Wildes F, Takagi T, Chen ZH, et al. Nanoplex delivery of siRNA and prodrug enzyme for multimodality image-guided molecular pathway targeted cancer therapy. ACS Nano. 2010; 4: 6707–6716. PubMed: https://pubmed.ncbi.nlm.nih.gov/20958072/
  144. Bae KH, Lee K, Kim C, Park TG. Surface functionalized hollow manganese oxide nanoparticles for cancer targeted siRNA delivery and magnetic resonance imaging. Biomaterials. 2011; 32: 176–184. PubMed: https://pubmed.ncbi.nlm.nih.gov/20934746/
  145. Zhou Z, Huang D, Bao J, Chen Q, Liu G, et al. A synergistically enhanced T(1)–T(2) dual-modal contrast agent. Adv Mater. 2012; 24: 6223–6228. PubMed: https://pubmed.ncbi.nlm.nih.gov/22972529/
  146. Wang X, Zhou Z, Wang Z, Xue Y, Zeng Y, et al. Gadolinium embedded iron oxide nanoclusters as T1–T2 dual-modal MRI-visible vectors for safe and efficient siRNA delivery. Nanoscale. 2013; 5: 8098–8104. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3775844/
  147. Liang HD, Blomley MJK. The role of ultrasound inmolecular imaging. Br J Radiol. 2003; 76: S140–S150. https://www.ncbi.nlm.nih.gov/pubmed/15572336/
  148. Shim MS, Kwon YJ. Stimuli-responsive polymers and nanomaterials for gene delivery and imaging applications. Adv Drug Deliv Rev. 2012; 64: 1046–1059. PubMed: https://pubmed.ncbi.nlm.nih.gov/22329941/
  149. Unger, Porter T, Lindner J, Grayburn P. Cardiovascular drug delivery with ultrasound and microbubbles. Adv Drug Deliv Rev. 2014; 72: 110–126. PubMed: https://pubmed.ncbi.nlm.nih.gov/24524934/
  150. Martin KH, Dayton PA. Current status and prospects for microbubbles in ultrasound theranostics, Wiley Interdiscip. Rev Nanomed Nanobiotechnol. 2013; 5: 329–345. PubMed: https://pubmed.ncbi.nlm.nih.gov/23504911/
  151. Florinas S, Kim J, Nam K, Janat-Amsbury MM, Kim SW. Ultrasound-assisted siRNA delivery via arginine-grafted bioreducible polymer and microbubbles targeting VEGF for ovarian cancer treatment. J Control Release. 183: 1–8. PubMed: https://pubmed.ncbi.nlm.nih.gov/24657947/
  152. Vandenbroucke RE, Lentacker I, Demeester J, De Smedt SC, et al. Ultrasound assisted siRNA delivery using PEG-siPlex loaded microbubbles. J Control Release. 2008; 126: 265–273. PubMed: https://pubmed.ncbi.nlm.nih.gov/18237813/
  153. Liu Y, Miyoshi H, Nakamura M. Encapsulated ultrasoundmicrobubbles: therapeutic application in drug/gene delivery. J Control Release. 2006; 114: 89–99. PubMed: https://pubmed.ncbi.nlm.nih.gov/16824637/
  154. Chen CC, Sheeran PS, Wu SY, Olumolade OO, Dayton PA, et al. Targeted drug delivery with focused ultrasound-induced blood–brain barrier opening using acoustically-activated nanodroplets. J Control Release. 2013; 172: 795–804. PubMed: https://pubmed.ncbi.nlm.nih.gov/24096019/
  155. Cheng X, Li H, Chen Y, Luo B, Liu X, et al. Ultrasound-triggered phase transition sensitive magnetic fluorescent nanodroplets as a multimodal imaging contrast agent in rat and mouse model. PLoS ONE. 2013; 8: e85003. PubMed: https://pubmed.ncbi.nlm.nih.gov/24391983/
  156. Dayton PA, Zhao S, Bloch SH, Schumann P, Penrose K, et al. Application of ultrasound to selectively localize nanodroplets for targeted imaging and therapy. Mol Imaging. 2006; 5: 160–174. PubMed: https://pubmed.ncbi.nlm.nih.gov/16954031/
  157. Jian J, Liu C, Gong Y, Su L, Zhang B, et al. India ink incorporated multifunctional phase-transition nanodroplets for photoacoustic/ultrasound dual-modality imaging and photoacoustic effect based tumor therapy. Theranostics. 2014; 4: 1026–1038. PubMed: https://pubmed.ncbi.nlm.nih.gov/25161702/
  158. Horie S, Watanabe Y, Ono M, Mori S, Kodama T. Evaluation of antitumor effects following tumor necrosis factor-alpha gene delivery using nanobubbles and ultrasound. Cancer Sci. 2011; 102: 2082–2089. PubMed: https://pubmed.ncbi.nlm.nih.gov/21824220/
  159. Wang CH, Huang YF, Yeh CK. Aptamer-conjugated nanobubbles for targeted ultrasound molecular imaging. Langmuir. 2011; 27: 6971–6976. PubMed: https://pubmed.ncbi.nlm.nih.gov/21553884/
  160. Yin T, Wang P, Li J, Wang Y, Zheng B, et al. Tumorpenetrating codelivery of siRNA and paclitaxel with ultrasound-responsive nanobubbles hetero-assembled from polymeric micelles and liposomes. Biomaterials. 2014; 35: 5932–5943. PubMed: https://pubmed.ncbi.nlm.nih.gov/24746965/
  161. Chen Z, Liang K, Liu J, Xie M, Wang X, et al. Enhancement of survivin gene downregulation and cell apoptosis by a novel combination: liposome microbubbles and ultrasound exposure. Med Oncol. 2009; 26: 491–500. PubMed: https://pubmed.ncbi.nlm.nih.gov/19137432/
  162. Castle J, Butts M, Healey A, Kent K, Marino M, et al.Ultrasoundmediated targeted drug delivery: recent success and remaining challenges. Am J Physiol Heart Circ Physiol. 2013; 304: H350–H357. PubMed: https://pubmed.ncbi.nlm.nih.gov/23203969/
  163. Kaneko OF, Willmann JK. Ultrasound for molecular imaging and therapy in cancer. Quant Imaging Med Surg. 2012; 2: 87–97. PubMed: https://pubmed.ncbi.nlm.nih.gov/23061039/
  164. Son S, Min HS, You DG, Kim BS, Kwon IC. Echogenic nanoparticles for ultrasound technologies: evolution from diagnostic imaging modality to multimodal theranostic agent. Nano Today. 2012; 9: 525–540. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4672021/ V
  165. Sboros V. Response of contrast agents to ultrasound. Adv Drug Deliv Rev. 2008; 60: 1117–1136. PubMed: https://pubmed.ncbi.nlm.nih.gov/18486270/
  166. Carson AR, McTiernan CF, Lavery L, Grata M, Leng X, et al. Ultrasound-targeted microbubble destruction to deliver siRNA cancer therapy. Cancer Res. 2012; 72: 6191–6199. PubMed: https://pubmed.ncbi.nlm.nih.gov/23010078/
  167. Zhou QL, Chen ZY, Wang YX, Yang F, Lin Y, et al. Ultrasound-mediated local drug and gene delivery using nanocarriers. Biomed Res Int. 2014; e963891. PubMed: https://pubmed.ncbi.nlm.nih.gov/25202710/
  168. Yin T, Wang P, Li J, Zheng R, Zheng B, et al. Ultrasoundsensitive siRNA-loaded nanobubbles formed by hetero-assembly of polymeric micelles and liposomes and their therapeutic effect in gliomas. Biomaterials. 2013; 34: 4532–4543. PubMed: https://pubmed.ncbi.nlm.nih.gov/23522375/
  169. Lee DE, Koo H, Sun IC, Ryu TH, Kim K, et al. Multifunctional nanoparticles for multimodal imaging and theragnosis. Chem Soc Rev. 2012; 41: 2656–2672. PubMed: https://pubmed.ncbi.nlm.nih.gov/22189429/
  170. Choi HS, Frangioni JV. Nanoparticles for biomedical imaging: fundamentals of clinical translation. Mol Imaging. 2010; 9: 291–310. PubMed: https://pubmed.ncbi.nlm.nih.gov/21084027/
  171. Louie AY. Multimodality imaging probes: design and challenges. Chem Rev. 2010; 110: 3146–3195. PubMed: https://pubmed.ncbi.nlm.nih.gov/20225900/
  172. Boerman OC, Oyen WJG. Multimodality probes: amphibian cars for molecular imaging. J Nucl Med. 2008; 49: 1213–1214. PubMed: https://pubmed.ncbi.nlm.nih.gov/18632805/
  173. Idee JM, Louguet S, Ballet S, Corot C0 Theranostics and contrast-agents for medical imaging: a pharmaceutical company viewpoint. Quant Imaging Med Surg. 2013; 3: 292–297. PubMed: https://pubmed.ncbi.nlm.nih.gov/24404442/
  174. Wang YX. Physical scientists research biomedicine: a call for caution. Chin J Cancer Res. 2015; 27: 94–95. PubMed: https://pubmed.ncbi.nlm.nih.gov/25717232/
  175. Medarova Z, Pham W, Farrar C, Petkova V, Moore A. in vivo imaging of siRNA delivery and silencing in tumors. Nat Med. 2007; 13: 372–377. PubMed: https://pubmed.ncbi.nlm.nih.gov/17322898/
  176. Mikhaylova M, Stasinopoulos I, Kato Y, Artemov D, Bhujwalla ZM, Imaging of cationic multifunctional liposome-mediated delivery of COX-2 siRNA. Cancer Gene Ther. 2009; 16: 217–226. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226392/
  177. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumorspecific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A. 2007; 104: 15549–15554. PubMed: https://pubmed.ncbi.nlm.nih.gov/17875985/
  178. Lammers T, Aime S, Hennink WE, Storm G, Kiessling F. Theranostic nanomedicine. Acc Chem Res. 2011; 44: 1029–1038. PubMed: https://pubmed.ncbi.nlm.nih.gov/21545096/
  179. Ma X, Zhao Y, Liang XJ, Theranostic nanoparticles engineered for clinic and pharmaceutics. Acc Chem Res. 2011; 44: 1114–1122. PubMed: https://pubmed.ncbi.nlm.nih.gov/21732606/
  180. Ryu JH, Koo H, Sun IC, Yuk SH, Choi K, et al. Tumor targetingmultifunctional nanoparticles for theragnosis: new paradigm for cancer therapy. Adv Drug Deliv Rev. 2012; 64: 1447–1458. PubMed: https://pubmed.ncbi.nlm.nih.gov/22772034/
  181. Lee DE, Koo H, Sun IC, Ryu JH, Kim K, et al. Multifunctional nanoparticles for multimodal imaging and theragnosis. Chem Soc Rev. 2012; 41: 2656–2672. PubMed: https://pubmed.ncbi.nlm.nih.gov/22189429/
  182. Lee N, Choi SH, Hyeon T. Nano-sized CT contrast agents. Adv Mater. 2013; 25: 2641–2660.
  183. Hallouard F, Anton N, Choquet P, Constantinesco A, Vandamme T. Iodinated blood pool contrast media for preclinical X-ray imaging applications–a review. Biomaterials. 2010; 31: 6249–6268. PubMed: https://pubmed.ncbi.nlm.nih.gov/20510444/
  184. Liu Y, Ai K, Lu L. Nanoparticulate X-ray computed tomography contrast agents: from design validation to in vivo applications. Acc Chem Res. 2012; 45: 1817–1827. https://pubs.acs.org/doi/abs/10.1021/ar300150c
  185. Lusic H, Grinstaff MW. X-ray-computed tomography contrast agents. Chem Rev. 2012; 113: 1641–1666. PubMed: https://pubmed.ncbi.nlm.nih.gov/23210836/
  186. Jin E, Lu ZR. Biodegradable iodinated polydisulfides as contrast agents for CT angiography. Biomaterials. 2014; 35: 5822–5829. PubMed: https://pubmed.ncbi.nlm.nih.gov/24768156/
  187. Choi KY, Liu G, Lee S, Chen X. Theranostic nanoplatforms for simultaneous cancer imaging and therapy: current approaches and future perspectives. Nanoscale. 2012; 4: 330–342. PubMed: https://pubmed.ncbi.nlm.nih.gov/22134683/
  188. Anton N, Vandamme TF. Nanotechnology for computed tomography: a real potential recently disclosed. Pharm Res. 2012; 31: 20–34. PubMed: https://pubmed.ncbi.nlm.nih.gov/23896738/
  189. Cormode DP, Naha PC, Fayad ZA. Nanoparticle contrast agents for computed tomography: a focus on micelles. Contrast Media Mol Imaging. 2014; 9: 37–52. PubMed: https://pubmed.ncbi.nlm.nih.gov/24470293/
  190. Li X, Anton N, Zuber G, Vandamme T. Contrast agents for preclinical targeted X-ray imaging. Adv Drug Deliv Rev. 2014; 76: 116–133. PubMed: https://pubmed.ncbi.nlm.nih.gov/25086373/
  191. Lee JY, Chung SJ, Cho HJ, Kim DD. Iodinated hyaluronic acid oligomer-based nanoassemblies for tumor-targeted drug delivery and cancer imaging. Biomaterials. 2016; 85: 218–231. PubMed: https://pubmed.ncbi.nlm.nih.gov/26874284/
  192. Deng H, Zhong Y, Du M, Liu Q, Fan Z, et al. Theranostic self-assembly structure of gold nanoparticles for NIR photothermal therapy and X-ray computed tomography imaging. Theranostics. 2014; 4: 904–918. PubMed: https://pubmed.ncbi.nlm.nih.gov/25057315/
  193. Zhu J, Zheng L, Wen S, Tang Y, Shen M, et al. Targeted cancer theranostics using alpha-tocopheryl succinate-conjugated multifunctional dendrimer-entrapped gold nanoparticles. Biomaterials. 2014; 35: 7635–7646. PubMed: https://pubmed.ncbi.nlm.nih.gov/24927683/
  194. Jiang Y, Chen J, Deng C, Suuronen EJ, Zhong Z. Click hydrogels, microgels and nanogels: emerging platforms for drug delivery and tissue engineering. Biomaterials. 2011; 35: 4969–4985. PubMed: https://pubmed.ncbi.nlm.nih.gov/24674460/
  195. Kabanov AV, Vinogradov SV. Nanogels as pharmaceutical carriers: finite networks of infinite capabilities. Angew Chem Int Ed. 2009; 48: 5418–5429. PubMed: https://pubmed.ncbi.nlm.nih.gov/19562807/
  196. Zhang X, Malhotra S, Molina M, Haag R. Micro-and nanogels with labile crosslinksfrom synthesis to biomedical applications. Chem Soc Rev. 2015; 44: 1948–1973.
  197. Chen W, Achazi K, Schade B, Haag R. Charge-conversional and reduction-sensitive poly (vinyl alcohol) nanogels for enhanced cell uptake and efficient intracellular doxorubicin release. J Control Release. 2015; 205: 15–24. PubMed: https://pubmed.ncbi.nlm.nih.gov/25445693/
  198. Morimoto N, Hirano S, Takahashi H, Loethen S, Thompson DH, et al. Selfassembled pH-sensitive cholesteryl pullulan nanogel as a protein delivery vehicle. Biomacromolecules. 2013; 14: 56–63. PubMed: https://pubmed.ncbi.nlm.nih.gov/23215439/
  199. Jiang L, Zhou Q, Mu K, Xie H, Zhu Y, et al. pH/temperature sensitive magnetic nanogels conjugated with Cy5.5-labled lactoferrin for MR and fluorescence imaging of glioma in rats. Biomaterials. 2013; 34: 7418–7428. PubMed: https://pubmed.ncbi.nlm.nih.gov/23810255/
  200. Steinhilber D, Witting M, Zhang X, Staegemann M, Paulus F, et al. Surfactant free preparation of biodegradable dendritic polyglycerol nanogels by inverse nanoprecipitation for encapsulation and release of pharmaceutical biomacromolecules. J Control Release. 2013; 169: 289–295. PubMed: https://pubmed.ncbi.nlm.nih.gov/23262202/
  201. Yang H, Wang Q, Chen W, Zhao Y, Yong T, et al. Hydrophilicity/ hydrophobicity reversable and redox-sensitive nanogels for anticancer drug delivery. Mol Pharm. 2015; 12: 1636–1647. PubMed: https://pubmed.ncbi.nlm.nih.gov/25833093/
  202. Zhang X, Achazi K, Steinhilber D, Kratz F, Dernedde J, et al. A facile approach for dual-responsive prodrug nanogels based on dendritic polyglycerols with minimal leaching. J Control Release. 2014; 174: 209–216. PubMed: https://pubmed.ncbi.nlm.nih.gov/24225227/
  203. Yang C, Wang X, Yao X, Zhang Y, Wu W, et al. Hyaluronic acid nanogels with enzyme-sensitive cross-linking group for drug delivery. J Control Release. 2015; 205: 206–217. PubMed: https://pubmed.ncbi.nlm.nih.gov/25665867/
  204. Chen W, Zheng M, Meng F, Cheng R, Deng C, et al. In situ forming reduction-sensitive degradable nanogels for facile loading and triggered intracellular release of proteins. Biomacromolecules. 3; 14: 1214–1222. PubMed: https://pubmed.ncbi.nlm.nih.gov/23477570/
  205. Wei X, Senanayake TH, Warren G, Vinogradov SV. Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for the targeting of CD44-positive and drug-resistant tumors. Bioconjug Chem. 2013; 24: 658–668. PubMed: https://pubmed.ncbi.nlm.nih.gov/23547842/
  206. Stefanello TF, Szarpak-Jankowska A, Appaix F, Louage B, Hamard L, et al. Thermoresponsive hyaluronic acid nanogels as hydrophobic drug carrier to macrophages. Acta Biomater. 2014; 10: 4750–4758. PubMed: https://pubmed.ncbi.nlm.nih.gov/25110287/
  207. Liang K, Ng S, Lee F, Lim J, Chung JE, et al. Targeted intracellular protein delivery based on hyaluronic acid-green tea catechin nanogels. Acta Biomater. 2016; 33: 142–152. PubMed: https://pubmed.ncbi.nlm.nih.gov/26785145/
  208. Water JJ, Kim Y, Maltesen MJ, Franzyk H, Foged C, et al. Hyaluronic acidbased nanogels produced by microfluidics-facilitated self-assembly improves the safety profile of the cationic host defense peptide novicidin. Pharm Res. 2015; 32: 2727–2735. PubMed: https://pubmed.ncbi.nlm.nih.gov/25813840/
  209. Park K, Lee MY, Kim KS, Hahn SK. Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine-hyaluronic acid conjugate. Biomaterials. 2010; 31: 5258–5265. PubMed: https://pubmed.ncbi.nlm.nih.gov/20378167/
  210. Zhong Y, Zhang J, Cheng R, Deng C, Meng F, et al. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts. J Control Release. 2015; 205: 144–154. PubMed: https://pubmed.ncbi.nlm.nih.gov/25596560/
  211. Oh EJ, Park K, Kim KS, Kim J, Yang JA, et al. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. J Control Release. 2010; 141: 2–12. PubMed: https://pubmed.ncbi.nlm.nih.gov/19758573/
  212. Park JK, Shim JH, Kang KS, Yeom J, Jung HS, et al. Solid free-form fabrication of tissue-engineering scaffolds with a poly (lactic-co-glycolic acid) grafted hyaluronic acid conjugate encapsulating an intact bone morphogenetic protein-2/poly (ethylene glycol) complex. Adv Funct Mater. 2011; 21: 2906–2912.
  213. Fan Y, Deng C, Cheng R, Meng F, Zhong Z. In situ forming hydrogels via catalystfree and bioorthogonal “tetrazole-alkene” photo-click chemistry. Biomacromolecules. 2013; 14: 2814–2821.
  214. Song W, Wang Y, Qu J, Lin Q. Selective functionalization of a genetically encoded alkene-containing protein via “photoclick chemistry” in bacterial cells. J Am Chem Soc. 2008; 130: 9654–9655. PubMed: https://pubmed.ncbi.nlm.nih.gov/18593155/
  215. Ganesh S, Iyer AK, Gattacceca F, Morrissey DV, Amiji MM. In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticles. J Control Release. 2013; 172: 699–706. PubMed: https://pubmed.ncbi.nlm.nih.gov/24161254/ 
  216. Li J, Huo M, Wang J, Zhou J, Mohammad JM, et al. Redox-sensitive micelles self-assembled from amphiphilic hyaluronic aciddeoxycholic acid conjugates for targeted intracellular delivery of paclitaxel. Biomaterials. 2012; 33: 2310–2320. PubMed: https://pubmed.ncbi.nlm.nih.gov/22166223/
  217. Yao HJ, Zhang YG, Sun L, Liu Y. The effect of hyaluronic acid functionalized carbon nanotubes loaded with salinomycin on gastric cancer stem cells. Biomaterials. 2014; 35: 9208–9223. PubMed: https://pubmed.ncbi.nlm.nih.gov/25115788/
  218. Kesharwani P, Banerjee S, Padhye S, Sarkar FH, Iyer AK. Hyaluronic acid engineered nanomicelles loaded with 3,4-difluorobenzylidene curcumin for targeted killing of CD44+ stem-like pancreatic cancer cells. Biomacromolecules. 2015; 16: 3042–3053. PubMed: https://pubmed.ncbi.nlm.nih.gov/26302089/
  219. Wang X, Zhang J, Cheng R, Meng F, Deng C, et al. Facile synthesis of reductively degradable biopolymers using cystamine diisocyanate as a coupling agent. Biomacromolecules. 2016; 17: 882–890.
  220. Yu Z, Ho LY, Lin Q. Rapid, photoactivatable turn-on fluorescent probes based on an intramolecular photoclick reaction. J Am Chem Soc. 2011; 133: 11912–11915. PubMed: https://pubmed.ncbi.nlm.nih.gov/21736329/
  221. Peng J, Qi T, Liao J, Fan M, Luo F, et al. Synthesis and characterization of novel dual-responsive nanogels and their application as drug delivery systems. Nanoscale. 2012; 4: 2694–2704.
  222. Shi Y, van Steenbergen MJ, Teunissen EA, Novo LS, Gradmann S, et al. π–π stacking increases the stability and loading capacity of thermosensitive polymeric micelles for chemotherapeutic drugs. Biomacromolecules. 2013; 14: 1826-1837. PubMed: https://pubmed.ncbi.nlm.nih.gov/23607866/
  223. Zhu Y, Wang XX, Chen J, Zhang J, Meng F, et al. Bioresponsive and fluorescent hyaluronic acid-iodixanol nanogels for targeted X-ray computed tomography imaging and chemotherapy of breast tumors. J Control Release. 2016; 244: 229–239. PubMed: https://pubmed.ncbi.nlm.nih.gov/27568289/
  224. Kobayashi H, Choyke PL. Target-cancer-cell-specific activatable fluorescence imaging probes: rational design and in vivo applications. Acc Chem Res. 2010; 44: 83–90. PubMed: https://pubmed.ncbi.nlm.nih.gov/21062101/
  225. Chauhan VP, Jain RK. Strategies for advancing cancer nanomedicine. Nat Mater. 2013; 12: 958–962. PubMed: https://pubmed.ncbi.nlm.nih.gov/24150413/
  226. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010; 7: 653–664. PubMed: https://pubmed.ncbi.nlm.nih.gov/20838415/
  227. Liang L, Lin SW, Dai W, Lu JK, Yang TY, et al.Novel cathepsin B-sensitive paclitaxel conjugate: higher water solubility, better efficacy and lower toxicity. J Control Release. 2012; 160: 618–629. PubMed: https://pubmed.ncbi.nlm.nih.gov/22410114/
  228. Zou Y, Song Y, Yang W, Meng F, Liu H, et al. Galactose-installed photocrosslinked pH-sensitive degradable micelles for active targeting chemotherapy of hepatocellular carcinoma in mice. J Control Release. 2014; 193: 154–161. PubMed: https://pubmed.ncbi.nlm.nih.gov/24852094/
  229. Loutfy H. Madkour Book: Reactive Oxygen Species (ROS), Nanoparticles, and Endoplasmic Reticulum (ER) Stress-Induced Cell Death Mechanisms. Paperback. https://www.elsevier.com/books/reactive-oxygen-species-ros-nanoparticles-and-endoplasmic-reticulum-er-stress-induced-cell-death-mechanisms/madkour/978-0-12-822481-6
  230. Xu A, Chen J, Peng H, Han G, Cai H. Simultaneous interrogation of cancer omics to identify subtypes with significant clinical differences[J]. Front Genet. 2019; 10: 236. PubMed: https://pubmed.ncbi.nlm.nih.gov/30984238/
  231. Madkour LH. Book. Nanoparticles Induce Oxidative and Endoplasmic Reticulum Antioxidant Therapeutic Defenses. https://www.springer.com/gp/book/9783030372965?utm_campaign=3_pier05_buy_print&utm_content=en_08082017 &utm_medium=referral&utm_source=google_books#otherversion=9783030372972     
  232. Chen J, Han G, Xu A, Cai H. Identification of Multidimensional Regulatory Modules through. Multi-graph Matching with Network Constraints. IEEE Trans Biomed Eng. 2020; 67: 987-998. PubMed: https://pubmed.ncbi.nlm.nih.gov/31295100/
  233. Madkour LH. Book: Nucleic Acids as Gene Anticancer Drug Delivery Therapy. 1st Edition. https://www.elsevier.com/books/nucleic-acids-as-gene-anticancer-drug-deliverytherapy/madkour/978-0-12-819777-6
  234. Madkour LH. Book: Nanoelectronic Materials: Fundamentals and Applications (Advanced Structured Materials) 1st ed. 2019. https://www.springer.com/gp/book/9783030216207
  235. Wang YXJ, Choi Y, Chen ZY, Laurent S, Gibbs SL. Molecular imaging: from bench to clinic. Biomed Res Int. 2014; 357258. PubMed: https://pubmed.ncbi.nlm.nih.gov/25610862/
  236. Wang J, Mi P, Lin G, Xiáng Y, Wáng J, et al. Imaging-guided delivery of RNAi for anticancer treatment. Adv Drug Deliv Rev. 2016; 104: 44–60. PubMed: https://pubmed.ncbi.nlm.nih.gov/26805788/

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Figure 1

Figure 3

Figure 1

Figure 4

Figure 1

Figure 5

Figure 1

Figure 6

Figure 1

Figure 7

Figure 1

Figure 8

Figure 1

Figure 9

Figure 1

Figure 10

Figure 1

Figure 11

Figure 1

Figure 12

Figure 1

Figure 13

Figure 1

Figure 14

Figure 1

Figure 15

Figure 1

Figure 16

Figure 1

Figure 17

Figure 1

Figure 18

Figure 1

Figure 19

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Contact

Editorial Office Emails:

info@hspioa.org

amelia.sandra@hspioa.us

elena.maya@hspioa.us

Select by Volume & Issue

Submit Manuscript Information for Authors Advisory Board Rss Feed Articles Rss Feed

Most Viewed Keywords

University/Institution

Select and search by University/Institution.

Articles by Country

Select and search by country to get related articles.

Testmonials

I would like to thank JPRA for taking this decision. I understand the effort it represents for you. I'm truly happy to have the paper published in JPRA. And I'll certainly consider JPRA for my next publications as I was satisfied of the service provided, the efficiency and promptness of the interactions we had.

Emmanuel BUSATO

Publishing with the International Journal of Clinical and Experimental Ophthalmology was a rewarding experience as review process was thorough and brisk. Their visibility online is second to none as their published articles appear in all search engines. I will encourage researchers to publish with them.

Elizabeth Awoyesuku

“The choice to submit the forensic case study to the Journal of Addiction Therapy and Research was dictated by the match between the content and the potential readership. The publication process proved to be expedient and we were provided with constructive feedback from reviewers. The final article layout is attractive and conforms to standards. All-in-all, it has been a rewarding process.”

Elisabeth H Wiig

Archives of Vascular Medicine is one of the top class journal for vascular medicine with highly interesting topics. You did a professional and great Job!

Elias Noory

Thank you very much. I think the review process and all of what concerns the administration of the publication concerning our paper has been excellent. The nice and quick answers have been very good I think.

Doris Nilsson

Journal of Pulmonary and Respiratory Research is good journal for respiratory research purposes. It takes 2-3 weeks maximum for review of the manuscript to get published and any corrections to be made in the manuscript. It needs good articles and studies to get publish in the respiratory medicine. I am really glad that this journal editors helped me to get my case report published.

Divya Khanduja

Thanks you and your colleague for the great help for our publication. You always provide prompt responses and high quality of service. I am so happy to have you working with me. Thanks again!

Diana (Ding) Dai

Service and process were excellent as was the “look” of the article when published.

Deane Waldman

Great, thank you! It was very efficient working w/ your group. Very thorough reviews (i.e., plagiarism, peer, etc.). Would certainly recommend that future authors consider working w/ your group.

David W Brett

Your services are very good

Chukwuka Ireju Onyinye

I very much appreciate the humanitarian services provided in my stead by this journal/publisher. It exhibits total absence of editorial impertinence. As an Author, I have been guided to have a fruitful experience. The editorial care is highly commendable.

Chrysanthus Chukwuma

"An amazing experience with the Journal of Advanced Pediatrics and Child Health. Very fast blind review with pertinent corrections and suggestions. I highly recommand both the journal and the editor."

Chaimae Khairoun

The submission is very easy and the time from submission to response from the reviewers is short. Correspondence with the journal is nice and rapid.

Catrin Henriksson

The Clinical Journal of Obstetrics and Gynecology is an open access journal focused on scientific knowledge publication with emphasis laid on the fields of Gynecology and Obstetrics. Their services toward us have been encouraging through their kindness and respect. Great consideration has been given to us as young budding researchers and we are very grateful for this.

Carole Assontsa

During the process your positive communication, prompt feedback and professional approach is very highly appreciated. We would like to thank you very much for your support.

Can Vuran

I do appreciate for your service including submission, analysis, review, editorial and publishing process. I believe these esteemed journal enlighten the science with its high-quality personel.

Bora Uysal

I am very much pleased with the fast track publication by your reputed journal's editorial team. It is really helpful for researchers like me from developing nations. I strongly recommend your journal for publication.

Badri Kumar Gupta

It has been a fabulous journey writing articles for your journal because of the encouragement you people provide for writers from developing nations like India. Kindly continue the same. Looking forward for a long term association.

Badareesh Lakshminarayana

Many thanks for publishing my article in your great journal and the friendly and hassle-free publication process, the constructive peer-review, the regular feedback system, and the Quick response to any queries.

Azab Elsayed Azab

I would like to thank this journal for publishing my Research Article. Something I really appreciate about this journal is, they did not take much time from the day of Submission to the publishing date. Looking forward to have more publications in future.

Ayush Chandra

Submission of paper was smooth, the review process was fast. I had excellent communication and on time response from the editor.

Ayokunle Dada

Your service is very good and fast reply, also your service understand our situation and support us to publication our articles.

Ayman M Abu Mustafa

Really good service with prompt response. Looking forward to having long lasting relationship with your journal

Avishek Bagchi

Your service is excellent. Processing and editing were very fast. I hope to publish more of my works in your journal.

Ausraful Islam

I wanna to thank Clinical Journal of Nursing Care and Practice for its effort to review and publish my manuscript. This is reputable journal. Thank you!

Atsedemariam Andualem

“It was a delightful experience publishing my manuscript with the Clinical Journal of Obstetrics and Gynecology. They offered me lots of opportunities I never had from most publishing houses and their prompt services are greatly appreciated.”

Asafo Jones

I hope to ability to make some new investigation and publish in Your Company in future.

Artur Stopyra

I like the quality of the print & overall service. The paper looks quite impressive. Hope this will attract interested readers. All of you have our best wishes for continued success.

Arshad Khan

Your big support from researchers around the world is the best appreciation from your scientific teams. We believe that there should be no barrier in science and you make it real and this motto come true.

Arefhosseinir Rafi

Your journal co-operation is very appreciable and motivational. I am really thankful to your journal and team members for the motivation and collaboration to publish my work.

Assistant Professor, UCLAS Uttaranchal University, Dehradun, India

Archna Dhasmana

I am glad to submit the article to Heighten Science Publications as it has a very smooth and fast peer-review process, which enables the researchers to communicate their work on time.

Anupam M

This is to specify that I have had an extensive and detailed interaction with the Editorial team of Annals of Clinical Gastroenterology and Hepatology, USA, lasting over a significant period of time. My interaction has been extremely pleasant, especially with Ms Allie Smith, as I find the communication quite inspiring and crystal clear. The attitude of aforesaid individuals is quite helpful and guiding in pertinent instances. It has been a commemorative journey so far working with the Journal and I hope that the symbiosis will continue, evolve and flourish in the forthcoming years. I wish the journal, related personnel and aforementioned individuals a fruitful, successful run.

New Delhi, India

Anubha Bajaj

We appreciate the fact that you decided to give us full waiver for the applicable charges and approve the final version. You did an excellent job preparing the PDF version. Of course we will consider your magazine for our future submissions and we will pay the applicable fees then.

Anna Dionysopoulou

''Co-operation of Archives of Surgery and Clinical Research journal is appreciable. I'm impressed at the promptness of the publishing staff and the professionalism displayed. Thank you very much for your support, help and encouragement.''

Anıl Gokce

Congratulations for the excellence of your journal and high quality of its publications.

Angel MARTIN CASTELLANOS

The service from the journal staff has been excellent.

Andy Smith

I was very pleased with the quick editorial process. We are sure that our paper will have great visibility, among other things due to its open access. We believe in science accessible to all.

Anderson Fernando de Souza

It was a great experience publishing through JCICM. The article has reached out to several institutions. Appreciate your professional work. Hope to work with you again

Anas Wardeh

Publishing an article is a long process, but working with your publication department made things go smoothly, even though the process took exactly 5 months from the time of submitting the article till the time I have favourable response, the missing part is the peer review details, which is essential in self auditing and future improvement, overall experience was excellent giving your understanding of the situation of lack of financial institution support.

Anas Diab

I think that Heighpubs very good. You are very helpful. Thank you for everything.

Ana Ribeiro

Regarding to be services, we note that are work with high standards of professionalism translated into quick response, efficiency which makes communication accessible. Furthermore, I believe to be much inviting for the submission of future works for publication purposes.

Amélia João Alice Nkutxi

I would like to mention that I had a wonderful experience working with HSPI. The whole process right from manuscript submission to peer review till the publication of the article was very prompt & efficient. I wish you good luck for the future.

Amarjeet Gambhir

Once I submitted the manuscript, the response time of the reviewers was very fast. The fine-tuning of the galley proof was likewise prompt. I believe the journal provide a valuable outlet to disseminate physical rehabilitation scientific knowledge to the clinical community. Respectfully. Dr. Alon

Alon

We really appreciate and thanks the full waiver you provide for our article. We happy to publish our paper in your journal. Thank you very much for your good support and services.

Ali Abusafia

It was a real pleasure working with your team. The review was done fast, and it was very clear, the editing was flawless, the article was published quickly compared to other journals, and everyone was understanding and helpful. I will gladly recommend this journal to my acquaintances in academia.

Alexandra Cozma

To the editorial team at HSPI and the Journal of Clinical Nephrology: Thank you so much for your hard work and collaboration in bringing our article to life. Your staff was responsive, flexible, and communicative and made the process smooth and easy. Thank you!

Alejandro Munoz

Dear colleagues! I am satisfied with our cooperation with you. Your service is at a high level. I hope for a future relationship. Let me know if I can get a paper version of the magazine with my articles from you. I see them on the Internet.

Aksenov V.V

"This is my first time publishing with the journal/publisher. I am impressed at the promptness of the publishing staff and the professionalism displayed. Thank you for encouraging young researchers like me!"

Ajite Kayode

I want to thank you for our collaboration. You were fast and effective with a positive spirit of teamwork. I am truly excited from our collaboration. You were like always fast, efficient and accurate. I hope that in the near future we will collaborate again.

Aikaterini Solomou

In my opinion, you provide a very fast and practical service.

Ahmet Eroglu

Great, We are too comfortable with the process including the peer review process and quality. But, the journal should be indexed in different databases such scopus.

Afework Edmealem

We really appreciate your efforts towards our article, the professional way you handle our request for exemption from charges. It was a great honor for us to publish in your magazine.

Achraf elbakkaly

I really liked the ease of submitting my manuscript in the HSPI journal. Further, the peer review was timely completed and I was communicated the final decision on my manuscript within 10 days of submission which is really appreciable. I strongly recommend all the scientists and researchers to submit their work in this journal”

Abu Bashar

My candid opinion is that the service you render is second to none. My favourite part is the prompt response to issue, really i value that.

Abiodun Akanbi Adeogun

Thank you very much for accepting our manuscript in your journal “International Journal of Clinical Virology”. We are very thankful to the esteemed team for timely response and quick review process. The editorial team of International Journal of Clinical Virology is too cooperative and well-mannered during the publication process. We are hopeful to publish many quality papers in your journal and I suggest the International Journal of Clinical Virology to all of my colleagues, researchers and friends to publish their research here.

Abdul Baset

I, Muhammad Sarwar Khan, am serving as Editor on Archives of Biotechnology and Biomedicine (ABB). I submitted an editorial titled, 'Edible vaccines to combat Infectious Bursal Disease of poultry' for publication in ABB. After submitting the manuscript; the services rendered by the management and technical personnel to handle and process the manuscript were marvelous. Plagiarism report was shared with me with complements before reviewers' comments, All steps including article processing and service charges were well taken care of keeping in view the author's interest/preference. All together, it was an encouraging and wonderful experience working with ABB personnel.

University of Agriculture, Pakistan

Muhammad Sarwar Khan

Your journal has accomplished its intended mission of providing very effective and efficient goals in dealing with submissions, conducting the reviewing process and in publishing accepted manuscripts in a timely manner. Keep up the great work and services that you provide.

University of Jacqmar, Inc., USA

John St. Cyr

I am to express my view that Heighten Science Publications are reliable quick even after peer review process. I hope and wish the publications will go a long way in disseminating science to many interested in scientific research.

College of Fisheries, CAU(I), Tripura, India

Ajit Kumar Roy

The Journal Clinical Nephrology provides a good opportunity for readers to stay updated in the field of clinical nephrology. Additionally - it provides a good opportunity for authors to publish their work. 1. Publication of the accepted manuscripts is sufficiently rapid. 2. The trust factor between the journal and me, as an author, is very important and well preserved. 3. Peer review process very rapid and effective.

Assaf Harofeh Medical Center, Israel

Leonid Feldman

In 2017, I submitted a manuscript to the journal Archives of Biotechnology and Biomedicine belonging to Heighten Science Publications Corporation. Within one week I already received the response from the editor. All processing steps were really fast so in terms of a speedy publication I can particularly recommend the journal Archives of Biotechnology and Biomedicine. The responsible contact person of the journal was always available, which gives a trustworthy impression to the author. Also the peer review process was clear and constructive. So from my experience with Heighten Science Publications Corporation I can recommend publishing there.

University of Tubingen, Germany

Yvonne Mast

We thank to the heighten science family, who speed up the publication of our article and provide every support.

Mehmet Besir

The services of the journal were excellent. The most important thing for an author is the speed of the peer review which was really fast here. They returned in a few days and immediately replied all of my questions. I want to refer this platform to all scholars. Many thanks.

Eastern Mediterranean University, Cyprus

Zehra Guchan TOPCU

Thank you for your attitude and support. I am sincerely grateful to you and the entire staff of the magazine for the high professionalism and fast quality work. Thank you very much!

USA

Igor Klepikov

Thank you and your company for effective support of authors which are very much dependable on the funds gambling for science in the different countries of our huge and unpredictable world. We are doing our work and should rely on a teams like Galley Proof-HSPC. Great success to all of you for the 2019th! Be well all the year long.

Russia

Victor V Apollonov

The editorial process was quickly done. The galley proof was sent within a week after being accepted for publication. The editorial team was very helpful and responded promptly.

India

Rohit Kulshrestha

Publishing with the International Journal of Clinical and Experimental Ophthalmology was a rewarding experience as review process was thorough and brisk. Their visibility online is second to none as their published articles appear in all search engines. I will encourage researchers to publish with them.

University of Port Harcourt Teaching Hospital, Nigeria

Dr. Elizabeth A Awoyesuku

"It was a pleasure to work with the editorial team of the journal on the submission of the manuscript. The team was professional, fast, and to the point".

NC A&T State University, USA

Moran Sciamama-Saghiv

Submission of paper was smooth, the review process was fast. I had excellent communication and on time response from the editor.

Ekiti State University Teaching Hospital, Nigeria

Ayokunle Dada

I am delighted and satisfied with. Heighten Science Publications as my manuscript was thoroughly assessed and published on time without delay. Keep up the good work.

Ido-Ekiti/Afe Babalola University, Nigeria

Dr. Shuaib Kayode Aremu

"This is my first time publishing with the journal/publisher. I am impressed at the promptness of the publishing staff and the professionalism displayed. Thank you for encouraging young researchers like me!"

Ekiti State University, Nigeria

Adebukola Ajite

I wanna to thank clinical journal of nursing care and practice for its effort to review and publish my manuscript. This is reputable journal. Thank you!

Wollo University, Ethiopia

Atsedemariam Andualem

We appreciate your approach to scholars and will encourage you to collaborate with your organization, which includes interesting and different medical journals. With the best wishes of success, creativity and joy in life, prosperity in the medical field.

Ivano- Frankivsk National Medical University, Ukraine

Nataliya Kitsera

Thank you very much for your support and encouragement. I am truly impressed by your tolerance and support. Thank you very much

Diaverum: PADC, Jeddah, Saudi Arabia

Nasrulla Abutaleb

You are such a nice person. Your journal co-operation is very appreciable and motivational.

Department of Biotechnology, Uttaranchal college of Applied and Life Sciences, Uttaranchal University, Dehradun, Uttarakhand, India

Archna Dhasmana

“Mobile apps and wearable technology are becoming ubiquitous in our environment. Their integration with healthcare delivery is just beginning to take shape. The early results are promising and the possibilities great."

BS, PharmD., MBA, CPHIMS, FHIMSS, Adjunct Professor, Global Healthcare Management, MCPHS University, Chief Strategy Offi cer, MedicaSoft, Senior Advisor, National Health IT (NHIT) Collaborative for Underserved, New York HIMSS, National Liaison, Health 2.0 Boston, Past Chair, Chair Innovation, USA

Helen Figge

“The choice to submit the forensic case study to the Journal of Addiction Therapy and Research was dictated by the match between the content and the potential readership. The publication process proved to be expedient and we were provided with constructive feedback from reviewers. The final article layout is attractive and conforms to standards. All-in-all, it has been a rewarding process.”

Ph.D, Boston University Department of Communication Sciences and Disorders and Knowledge Research Institute, Inc., 2131 Reflection Bay Drive, Arlington, Texas 76013, USA

Elisabeth H. Wiig

The service is nice and the time of processing the application is fast.

Department of Neurosurgery, Queen Elizabeth Hospital, Hong Kong

Long Ching

Your service is very good and fast reply, Also your service understand our situation and support us to publication our articles.

Palestine College of Nursing, Khan Younis, Gaza Strip, Palestine

Ayman M Abu Mustafa

“It was a delightful experience publishing my manuscript with the Clinical Journal of Obstetrics and Gynecology. They offered me lots of opportunities I never had from most publishing houses and their prompt services are greatly appreciated.”

Department of Agricultural Economics, Agribusiness and Extension, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana

Akowuah Jones Asafo

View More

Related Journals

Help ?